



REFERENCES

Aryandono, T, 2006, 'Semakin tinggi penderita kanker payudara di usia muda', *humasugm*, viewed 19 March 2014, www.ugm.ac.id/id/berita/1811.semakin.tinggi.penderita.kanker.di.usia.muda

Badan Registrasi Kanker (BRK-IAPI). 1992 - 2002. Laporan Tahunan.

Baxter, S. and Campbell, I. (2001). Re: Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk. *JNCI Journal of the National Cancer Institute*, 93(7), pp.557-558.

Cancer Research UK.2008. *UK Breast Cancer incidence statistics*.

ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5 Version 2.0. IARC Press, Lyon

Ferri, F. (2016). *Ferri's clinical advisor 2016*.

Hartley MC, McKinley BP, Rogers EA, Kalbaugh CA, Messich HS, Blackhurst DW et al (2006) Differential expression of prognostic factors and effect on survival in young (< or = 40) breast cancer patients: a case-control study. *Am Surg* 72:1189-1194

Hishida, A. (2002). Re: Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk. *CancerSpectrum Knowledge Environment*, 94(23), pp.1807-1808.



Jemal A, Ward E, Thun MJ. 2007. *Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Research.* 9:3 Kumar V, Abbas AK, Fausto N, Mitchell RN. 2007. *Robbins Basic Pathology.* Saunders Elsevier Philadelphia

Lee, S., Hou, M., Hsieh, P., Wu, S., Ann Hou, L., Ma, H., Tsai, S. and Tsai, L. (2008). A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan. *Clinical Biochemistry*, 41(3), pp.121-125.

Maliki, FA 2012, *eksistensi sel stem kanker (ALDH1+) pada karsinoma payudara duktal infiltratif dan hubungannya dengan ekspresi HER2*, thesis, Yogyakarta, Universitas gadjah Mada

Millikan, R., Hummer, A., Wolff, M., Hishida, A. and Begg, C. (2005). HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses. *Breast Cancer Res Treat*, 89(3), pp.309-312.

Musolino, A., Bella, M., Bortesi, B., Michiara, M., Naldi, N., Zanelli, P., Capelletti, M., Pezzuolo, D., Camisa, R., Savi, M., Neri, T. and Ardizzoni, A. (2007). BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study. *The Breast*, 16(3), pp.280-292.

Ries LAG, Melbert D, Krapcho M, Marriotto A, Miller BA, Feuer EJ et al (2007a) SEER cancer statistics review, 1975-2004. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER website



Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E (2003) Breast cancer in young women: clinicopathological features and biological specificity. *Breast* 12:247-250

Winchester, DJ & Winchester, DP 2000, *American cancer society atlas of clinical oncology: breast cancer*, B.C. Decker inc. London

Xie, D. (2000). Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk. *Journal of the National Cancer Institute*, 92(5), pp.412-417.

Zahl PH, Strand BH, Mählen J. 2004. *Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. British Med J.* 328;921-924.

Zimmerman, BT 2003, *Understanding Breast Cancer Genetics*, University Press of Mississippi, Jackson